GlassScriptPhysician profile
Steven Richard Devore Best
NPI 1730201567
$14,193.99
in general payments reported to CMS, 2019-2025
46 companies · $2,559 in 2025
The $2,559 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,311 · 2020: $1,514 · 2021: $2,622 · 2022: $2,075 · 2023: $2,148 · 2024: $1,966 · 2025: $2,559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,566 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,565.75 |
| Education | $106.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,769.99 | 2021-2025 | Vraylar, Ubrelvy |
| Harmony Biosciences LLC | $1,431.75 | 2020-2025 | Wakix |
| Alkermes, INC. | $1,142.65 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $1,066.46 | 2019-2025 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $976.24 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $912.55 | 2019-2025 | Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $718.91 | 2020-2025 | Trintellix |
| Jazz Pharmaceuticals INC. | $678.05 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $555.61 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Allergan, INC. | $512.35 | 2019-2020 | |
| Axsome Therapeutics, INC. | $509.65 | 2023-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $501.57 | 2019-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $315.18 | 2020-2024 | Invega Sustenna, Spravato |
| Noven Therapeutics, LLC | $286.73 | 2021-2025 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $236.69 | 2019-2024 | Jornay Pm |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Devore Best listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.